Search for: "In re Barr" Results 441 - 460 of 921
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Oct 2007, 11:35 am
The claims we're ticked off about at the moment involve a disconnect between the allegations and the facts. [read post]
11 Feb 2020, 11:53 am by Stewart Baker
Rather, they’re arguing that EARN IT will hurt end-to-end encryption. [read post]
19 Apr 2019, 9:31 am by Josh Blackman
” I suspect Barr’s disagreement may stem in part from Mueller’s threshold determination about the clear statement rule. [read post]
15 Mar 2010, 7:42 am by admin
“They’re busy, and it’s hard and it’s complicated and they’re trying to put it off. [read post]
29 Sep 2020, 6:13 pm by Anna Salvatore, Benjamin Wittes
Arguing for the government, Hashim Mooppan and Kenneth Kohl presented the more respectable, Bill Barr version of this story:  the department soberly reviewed an errant prosecution, found it wanting and, in the highest traditions of the department, decided not to proceed with it. [read post]
18 Nov 2020, 10:50 am by Anna Salvatore, Tia Sewell
“We’re running into Thanksgiving now and that’s only going to make it worse. [read post]
7 Jan 2018, 12:57 pm by Andrew Delaney
 This is the second round, but we haven’t gotten to the first one yet either, so we’re starting from scratch here. [read post]
7 Jan 2018, 12:57 pm by Andrew Delaney
 This is the second round, but we haven’t gotten to the first one yet either, so we’re starting from scratch here. [read post]
9 Sep 2010, 12:20 pm by FDABlog HPM
Barr Labs., Inc., (In re Tamoxifen Citrate Antitrust Litig.), 466 F.3d 187 (2d Cir. 2005), compelled it to do so: “Since Tamoxifen rejected antitrust challenges to reverse payments as a matter of law, we are bound to review the Cipro court’s rulings under the standard adopted in Tamoxifen. [read post]
4 May 2010, 11:40 am by FDABlog HPM
Barr Labs., Inc., (In re Tamoxifen Citrate Antitrust Litig.), 466 F.3d 187 (2d Cir. 2005), compelled it to do so: “Since Tamoxifen rejected antitrust challenges to reverse payments as a matter of law, we are bound to review the Cipro court’s rulings under the standard adopted in Tamoxifen. [read post]
7 Nov 2008, 3:42 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com]   Highlights this week included: US: CAFC affirms rejection of claim reciting broad genus of monoclonal antibodies for failure to satisfy written description requirement: In re Alonso… [read post]
3 Jun 2015, 9:55 am by Jennifer Driscoll and Helen C. Eckert
  However, in 2011 the court ruled that RE ‘516 was obtained by fraud on the patent office because Cephalon did not disclose that another company had invented the underlying drug formulation, thus invaliding the protection that would otherwise be accorded to RE ‘516. [read post]